Profil Pasien Hepatitis C Di Rsup Haji Adam Malik Medan
41
DAFTAR PUSTAKA
1. Theise ND. Hati, kandung empedu dan saluran bilier. In: Nassar IM, Cornain
S,
editors. Buku ajar patologi robbins edisi Bahasa Indonesia .9th
ed.Singapura: Saunders Elsevier; 2015. p. 604-610.
2. Kementerian Kesehatan Republik Indonesia.Badan Penelitian dan
Pengembangan Kesehatan : Riset kesehatan dasar 2013. Kementerian
Kesehatan Republik Indonesia:2013. p. 71-72
3. Hanafiah MK, Groeger J,Flaxman DA, Wiersma ST.Global epidemiology of
hepatitis C Virus Infection : new estimates of age-specific antibody to HCV
seroprevalance. J American Association for Study of Liver Diseases.2013 Apr
57(4):1333-1342.
4. Gani AR. Hepatitis C. In : Setiati S, Alwi I, Sudoyo AW, Marcelius SK,
Setiyahadi B, Syam AF, editors. Ilmu penyakit dalam Jilid II.6th ed. Jakarta;
Pusat Penerbitan Ilmu Penyakit Dalam; 2014. p. 1972-1977.
5. Kementrian Kesehatan Republik Indonesia. Pedoman pengendalian hepatitis
virus.Kementrian Kesehatan Republik Indonesia;2012. p.19-25.
6. Chang IC, Huang SF, Chen PJ,Chen CL,editors et al. The hepatitis viral status
in patients with hepatocellular carcinoma: a Study of 3843 Patients
From
Taiwan Liver Cancer Network.Medicine J.2016 Nov 95(15):1-9.
7. Davis LG, Alter JM, El-Serag H,Poynad T, Jennings LW.aging of hepatitis C
virus (HCV)-infected persons in United States : a multiple cohort model of
HCV prevalance and disease progression. J American Gastroenterological
Association.2010 feb 138(2):513-521.
8. Kementerian Kesehatan Republik Indonesia.Peraturan Menteri Kesehatan
Indonesia Nomor 53 Tahun 2015.Kementerian Kesehatan Republik
Indonesia;2015. p.28-31.
9. Snell RS. Sistem pencernaan. In: Suwahjo A, Lyestiawan YA, editors.
Anatomi klinis Berdasarkan sistem. Jakarta:EGC;2011. p. 722 - 730.
10. Nguyen TT, Liangappa VR. Penyakit hati. In: Dany F, editors. Patofisiologi
penyakit pengantar menuju kedokteran klinis. Jakarta:ECG;2011. p.421-453
11. Mescher AL.Organ-organ yang berhubungan dengan saluran cerna. In :
Hartanto
H,
editors.
Histologi
dasar
junqueira
teks
dan
th
atlas.12 ed.Jakarta.EGC;2011. p. 282 – 290.
Universitas Sumatera Utara
42
12. Netter FH. Abdomen. In: Atlas of Human Anatomy.5thed .Saunders
Elsevier,2010. p. 277.
13. Eroschenko VP, Editors. Sistem Pencernaan: hati, kandung empedu, dan
pankreas. In: Dharmawan D, Yesdelita N. Atlas histologi diFiore dengan
korelasi fungsional.11 th ed.Jakarta. ECG;2012. p. 332-333.
14. Messina JP,Humphreys I,Flaxman A, Brown A, Cooke GS,Pybus OG, Barnes
E.Global distribution and prevalance of hepatitis C virus genotype. J
American Association for Study of Liver Diseases.2015 Jan 61(1):77-87.
15. Tohme RA, Holmberg SD, Is sexual contact a major mode of hepatitis C virus
transmision?. J American Association for Study of Liver Diseases.2010Oct
52(4):1497-1505.
16. Liang TJ, Rehermann B,Seeff LB,Hoofnagle JH. Pathogenesis, natural
history,treatment,and prevention of hepatitis C.J Ann Intern Med.2000 Feb
132(4):296-305.
17. World Health Organization.Guidelines for screening care and treatment of
persons with hepatitis C infection.World Health Organization;2014. p. 30-31.
18. Jason MH, Sud A,Geoffrey CF,Bandara P, Byth K, James
GK,GeoffreyWM,George J.Insulin resistance is associates with chronic
hepatitis Cvirus infection
and fibrosis progression.J American
Gastroenterological Association.2003 Dec 125(6):1695-1704.
19. Missiha SB, Ostrowski M,Heathcote EJ.Disease Progression in
chronichepatitis C: modifiable and nonmodifiable factors. J American
Gastroenterological Association.2008 May 134(6):1699-1714.
20. European Association for Study of the Liver. EASL recommendation on
treatment of hepatitis C 205.European Association for Study of the
Liver;2015. p. 199-217.
21. Interna Publishing. Hepatologi. In: Alwi I, Salim S, Hidayat R, Kurniawan J,
Tahapary DL, editors. Penatalaksaan di bidang Ilmu penyakit dalam panduan
praktik klinis.jakarta.Pusat Penerbitan Ilmu PenyakitDalam;2014. p. 240- 241.
22. Asian Pasiffic Association for the Study of Liver. APASL consensus
statements and recommendation on treatment of hepatitis C.Asian Pasiffic
Association for the Study of Liver; 2016. p. 4-15.
23. American Association for the Study of Liver Diseases.Hepatitis Guidance :
AASLD-IDSA recommendations for testing, managing,and treating
Universitas Sumatera Utara
43
adultsinfected with hepatitis C virus.American Association for the Study of
Liver Diseases;2015. p. 937- 941.
24. Pearlman BL, Traub N.Sustained virologic response to antiviral therapy for
chronic hepatitis C Virus Infection: A cure and So Much More.J Oxford
University.2011 Sep 52(7): 889-900.
25. Louie KS, St Laurent S, Forssen UM, Mundy LM, Pimenta JM. The high
comorbidity burden of the hepatitis C Virus infected population in the United
States.BMC Infectious Diseases[Internet]. 2012 Apr [cited 24 Mei
2016]:12(86)
Available
from
Medscape
:http://www.medscape.com/viewarticle/770305.
26. Guadagnino V, Stroffolini T, Rapicetta M, Costantino A, Kondili LA,
Menniti-Ippolito F, Caroleo B, Costa C, Griffo G, Loiacono L, Pisani V, Foca
A, Piazza M. Prevalance, risk Factors, and genotype of hepatitis C virus
infection in general population : A community-based survey in southern Italy.
1997 May 26(4): 1006-1001.
27. Mohamoud YA, Mumtaz GR, Riome S, Miller D, Abu-Raddad LJ. The
epidemiology of hepatitis C virus in Egypt : a systematic review and data
synthesis. J BMC Infectious Diseases. 2013 June [cited 5 Dec 2016]
Avalailable
from
Biomed
Central
: https://bmcinfectdis.biomedcentral.com/articles/10.1186/1471-2334-13-288 .
28. Butterfield ML, Bosworth HB, Meador KG, Stechuchak KM, Essock SM,
Osher FC, Goodman LA, Swanson JW, Bastian LA, Horner RD. Blood Borne
Infections and Persons with mental illness : Gender differences in hepatitis C
infection and risks amon persons with sever mental illness. J psychiatry
online. 2003 June 54(6): 848-853.
29. Hezode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, Zafrani E,
Pawlostky J, Dhumeaux D, Lotersztajin S, Maliat A. Daily cannabis smoking
as a risk factor for progression of fibrosis in chronic hepatitis C. J American
Association for the Study of Liver Diseases 2005 May 42(1) : 63-71.
30. Pessione F, Ramond M, Njampoum C, Duchtelle V, Degott C, Erlinger S,
Rueff B, Valla D, Degos F. Cigarette smoking and hepatic lesion in patients
with chronic hepatitis C.J American Association for the Study of Liver
Diseases. 2001 July 34(1) : 121-12.
31. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL.
Prevalance of type 2 diabetes melitus among person with hepatitis C virus
infection in the united states. J Ann Intern Med.2000 Oct 133(8) 592-599.
Universitas Sumatera Utara
44
32. Wai CT, Greenson JK, Fontana RJ, Kalbfeisch JD, Marrero JA, Conjeevaram
HS, Lok AS. A simple noninvasive index can predict both significant fibrosis
and cirrhosis in patients with chronic hepatitis C. J American Association for
the Study of Liver Diseases. 2003 Mei 38(2): 518-526.
33. Pockros PJ, Duchini A, McMilan R, Nyberg LM, McHutchison J, Viernes E.
Immune thrombocytopenic purpura in patients with chronic hepatitis C virus
infection. 2002 Aug 97(8): 2040-5.
34. Fouad YM. Chronic hepatitis C –associated thrombocytopenia: aetiology and
management. J Tropical Gastroenterlogy and Endemic Medicine. 2013
34(2):58-67
35. Danish FA, Koul SS, Subhani FR, Rabbani AE, Yasmin S. Antiviral Therapy
in HCV-infected Decompensated Cirrotics. J Saudi Gastroenterol. 2010 Oct
16(4): 310-314.
36. Zein NN. Clinical significance of hepatitis C virus genotypes. J Mayo Clinic
and Mayo Foundation. 2000 Apr 13(2): 223-35.
37. Ellis EL, Mann DA. Clinical evidence for the regression of liver fibrosis. J
European Association for Study of the Liver. 2012 May 56(5):1711-1180.
38. Fried MW. Side effect of Therapy of Hepatitis C and Their management. . J
American Association for the Study of Liver Diseases. 2002 36(5) 237-234.
39. Hernandez MD, Sherman KE. HIV/HCV coinfection natural history and
disease progression, A review of the most recent literature. 2011 Nov 6(6):
478-482.
40. Ashgar HA, Helmy A, Khan MQ, Kahtani KA, Quaiz MA, Rezeig M, Kagevi
I, Alshehri A, Kalbani AA, Swat KA, Dahab S. Predictors of sustained
virological response to a 48 week course of pegylated interferon alfa-2a and
ribavirin in patients infected with hepatitis C virus genotype 4. 2009 Jan-Feb
29(1): 4-14.
Universitas Sumatera Utara
DAFTAR PUSTAKA
1. Theise ND. Hati, kandung empedu dan saluran bilier. In: Nassar IM, Cornain
S,
editors. Buku ajar patologi robbins edisi Bahasa Indonesia .9th
ed.Singapura: Saunders Elsevier; 2015. p. 604-610.
2. Kementerian Kesehatan Republik Indonesia.Badan Penelitian dan
Pengembangan Kesehatan : Riset kesehatan dasar 2013. Kementerian
Kesehatan Republik Indonesia:2013. p. 71-72
3. Hanafiah MK, Groeger J,Flaxman DA, Wiersma ST.Global epidemiology of
hepatitis C Virus Infection : new estimates of age-specific antibody to HCV
seroprevalance. J American Association for Study of Liver Diseases.2013 Apr
57(4):1333-1342.
4. Gani AR. Hepatitis C. In : Setiati S, Alwi I, Sudoyo AW, Marcelius SK,
Setiyahadi B, Syam AF, editors. Ilmu penyakit dalam Jilid II.6th ed. Jakarta;
Pusat Penerbitan Ilmu Penyakit Dalam; 2014. p. 1972-1977.
5. Kementrian Kesehatan Republik Indonesia. Pedoman pengendalian hepatitis
virus.Kementrian Kesehatan Republik Indonesia;2012. p.19-25.
6. Chang IC, Huang SF, Chen PJ,Chen CL,editors et al. The hepatitis viral status
in patients with hepatocellular carcinoma: a Study of 3843 Patients
From
Taiwan Liver Cancer Network.Medicine J.2016 Nov 95(15):1-9.
7. Davis LG, Alter JM, El-Serag H,Poynad T, Jennings LW.aging of hepatitis C
virus (HCV)-infected persons in United States : a multiple cohort model of
HCV prevalance and disease progression. J American Gastroenterological
Association.2010 feb 138(2):513-521.
8. Kementerian Kesehatan Republik Indonesia.Peraturan Menteri Kesehatan
Indonesia Nomor 53 Tahun 2015.Kementerian Kesehatan Republik
Indonesia;2015. p.28-31.
9. Snell RS. Sistem pencernaan. In: Suwahjo A, Lyestiawan YA, editors.
Anatomi klinis Berdasarkan sistem. Jakarta:EGC;2011. p. 722 - 730.
10. Nguyen TT, Liangappa VR. Penyakit hati. In: Dany F, editors. Patofisiologi
penyakit pengantar menuju kedokteran klinis. Jakarta:ECG;2011. p.421-453
11. Mescher AL.Organ-organ yang berhubungan dengan saluran cerna. In :
Hartanto
H,
editors.
Histologi
dasar
junqueira
teks
dan
th
atlas.12 ed.Jakarta.EGC;2011. p. 282 – 290.
Universitas Sumatera Utara
42
12. Netter FH. Abdomen. In: Atlas of Human Anatomy.5thed .Saunders
Elsevier,2010. p. 277.
13. Eroschenko VP, Editors. Sistem Pencernaan: hati, kandung empedu, dan
pankreas. In: Dharmawan D, Yesdelita N. Atlas histologi diFiore dengan
korelasi fungsional.11 th ed.Jakarta. ECG;2012. p. 332-333.
14. Messina JP,Humphreys I,Flaxman A, Brown A, Cooke GS,Pybus OG, Barnes
E.Global distribution and prevalance of hepatitis C virus genotype. J
American Association for Study of Liver Diseases.2015 Jan 61(1):77-87.
15. Tohme RA, Holmberg SD, Is sexual contact a major mode of hepatitis C virus
transmision?. J American Association for Study of Liver Diseases.2010Oct
52(4):1497-1505.
16. Liang TJ, Rehermann B,Seeff LB,Hoofnagle JH. Pathogenesis, natural
history,treatment,and prevention of hepatitis C.J Ann Intern Med.2000 Feb
132(4):296-305.
17. World Health Organization.Guidelines for screening care and treatment of
persons with hepatitis C infection.World Health Organization;2014. p. 30-31.
18. Jason MH, Sud A,Geoffrey CF,Bandara P, Byth K, James
GK,GeoffreyWM,George J.Insulin resistance is associates with chronic
hepatitis Cvirus infection
and fibrosis progression.J American
Gastroenterological Association.2003 Dec 125(6):1695-1704.
19. Missiha SB, Ostrowski M,Heathcote EJ.Disease Progression in
chronichepatitis C: modifiable and nonmodifiable factors. J American
Gastroenterological Association.2008 May 134(6):1699-1714.
20. European Association for Study of the Liver. EASL recommendation on
treatment of hepatitis C 205.European Association for Study of the
Liver;2015. p. 199-217.
21. Interna Publishing. Hepatologi. In: Alwi I, Salim S, Hidayat R, Kurniawan J,
Tahapary DL, editors. Penatalaksaan di bidang Ilmu penyakit dalam panduan
praktik klinis.jakarta.Pusat Penerbitan Ilmu PenyakitDalam;2014. p. 240- 241.
22. Asian Pasiffic Association for the Study of Liver. APASL consensus
statements and recommendation on treatment of hepatitis C.Asian Pasiffic
Association for the Study of Liver; 2016. p. 4-15.
23. American Association for the Study of Liver Diseases.Hepatitis Guidance :
AASLD-IDSA recommendations for testing, managing,and treating
Universitas Sumatera Utara
43
adultsinfected with hepatitis C virus.American Association for the Study of
Liver Diseases;2015. p. 937- 941.
24. Pearlman BL, Traub N.Sustained virologic response to antiviral therapy for
chronic hepatitis C Virus Infection: A cure and So Much More.J Oxford
University.2011 Sep 52(7): 889-900.
25. Louie KS, St Laurent S, Forssen UM, Mundy LM, Pimenta JM. The high
comorbidity burden of the hepatitis C Virus infected population in the United
States.BMC Infectious Diseases[Internet]. 2012 Apr [cited 24 Mei
2016]:12(86)
Available
from
Medscape
:http://www.medscape.com/viewarticle/770305.
26. Guadagnino V, Stroffolini T, Rapicetta M, Costantino A, Kondili LA,
Menniti-Ippolito F, Caroleo B, Costa C, Griffo G, Loiacono L, Pisani V, Foca
A, Piazza M. Prevalance, risk Factors, and genotype of hepatitis C virus
infection in general population : A community-based survey in southern Italy.
1997 May 26(4): 1006-1001.
27. Mohamoud YA, Mumtaz GR, Riome S, Miller D, Abu-Raddad LJ. The
epidemiology of hepatitis C virus in Egypt : a systematic review and data
synthesis. J BMC Infectious Diseases. 2013 June [cited 5 Dec 2016]
Avalailable
from
Biomed
Central
: https://bmcinfectdis.biomedcentral.com/articles/10.1186/1471-2334-13-288 .
28. Butterfield ML, Bosworth HB, Meador KG, Stechuchak KM, Essock SM,
Osher FC, Goodman LA, Swanson JW, Bastian LA, Horner RD. Blood Borne
Infections and Persons with mental illness : Gender differences in hepatitis C
infection and risks amon persons with sever mental illness. J psychiatry
online. 2003 June 54(6): 848-853.
29. Hezode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, Zafrani E,
Pawlostky J, Dhumeaux D, Lotersztajin S, Maliat A. Daily cannabis smoking
as a risk factor for progression of fibrosis in chronic hepatitis C. J American
Association for the Study of Liver Diseases 2005 May 42(1) : 63-71.
30. Pessione F, Ramond M, Njampoum C, Duchtelle V, Degott C, Erlinger S,
Rueff B, Valla D, Degos F. Cigarette smoking and hepatic lesion in patients
with chronic hepatitis C.J American Association for the Study of Liver
Diseases. 2001 July 34(1) : 121-12.
31. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL.
Prevalance of type 2 diabetes melitus among person with hepatitis C virus
infection in the united states. J Ann Intern Med.2000 Oct 133(8) 592-599.
Universitas Sumatera Utara
44
32. Wai CT, Greenson JK, Fontana RJ, Kalbfeisch JD, Marrero JA, Conjeevaram
HS, Lok AS. A simple noninvasive index can predict both significant fibrosis
and cirrhosis in patients with chronic hepatitis C. J American Association for
the Study of Liver Diseases. 2003 Mei 38(2): 518-526.
33. Pockros PJ, Duchini A, McMilan R, Nyberg LM, McHutchison J, Viernes E.
Immune thrombocytopenic purpura in patients with chronic hepatitis C virus
infection. 2002 Aug 97(8): 2040-5.
34. Fouad YM. Chronic hepatitis C –associated thrombocytopenia: aetiology and
management. J Tropical Gastroenterlogy and Endemic Medicine. 2013
34(2):58-67
35. Danish FA, Koul SS, Subhani FR, Rabbani AE, Yasmin S. Antiviral Therapy
in HCV-infected Decompensated Cirrotics. J Saudi Gastroenterol. 2010 Oct
16(4): 310-314.
36. Zein NN. Clinical significance of hepatitis C virus genotypes. J Mayo Clinic
and Mayo Foundation. 2000 Apr 13(2): 223-35.
37. Ellis EL, Mann DA. Clinical evidence for the regression of liver fibrosis. J
European Association for Study of the Liver. 2012 May 56(5):1711-1180.
38. Fried MW. Side effect of Therapy of Hepatitis C and Their management. . J
American Association for the Study of Liver Diseases. 2002 36(5) 237-234.
39. Hernandez MD, Sherman KE. HIV/HCV coinfection natural history and
disease progression, A review of the most recent literature. 2011 Nov 6(6):
478-482.
40. Ashgar HA, Helmy A, Khan MQ, Kahtani KA, Quaiz MA, Rezeig M, Kagevi
I, Alshehri A, Kalbani AA, Swat KA, Dahab S. Predictors of sustained
virological response to a 48 week course of pegylated interferon alfa-2a and
ribavirin in patients infected with hepatitis C virus genotype 4. 2009 Jan-Feb
29(1): 4-14.
Universitas Sumatera Utara